Loading…
VTGN
Vistagen Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 92840H400
$0.25-1.60%Price as of Aug 29, 18:33 UTC · updated once a day, after the close
Key metrics
- Market cap
- $11.22M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.5x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.66
- ROE
- -166.46%
- Profit margin
- 0.00%
- Revenue growth
- +504.90%
- Beta
- 0.38
- 52-week high
- $5.14
- 52-week low
- $0.20
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.6% over 5Y.
today you would have $3.32▼ -99.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $0.27 | $0.66 | $2.95 | $5.14 | $3.00 | $58.50 | $58.20 | $20.70 | $45.00 | $33.30 | $111.90 | $295.20 | $255.00 | $252.00 | $438.00 | $1,830.00 | |
| P/S | 18.6x |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MTVAMetaVia Inc. | $1.70 | — | 1.6x | — | -175.68% | $11.2M |
| TOVXTheriva Biologics, Inc. | $0.25 | 0.2x | 0.9x | — | -101.87% | $11.25M |
| ADGMAdagio Medical Holdings, Inc. | $0.51 | — | — | — | -657.76% | $11.35M |
| BLRXBioLineRx Ltd. | $2.60 |
About the company
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
- 41
- South San Francisco, United States
Company description provided by Yahoo Finance.